drugset / Trial / NCT03154840

Relative Bioavailability Among Different Eutropin Formulations

NCT03154840

Phase 1 Unknown 24 enrolled LG Chem
RandomizedCrossoverOpen-labelHealth-services research

Summary

1. Compares and evaluates the relative bioavailability of single-dose subcutaneous administration of each of the Eutropin formulations to healthy male volunteers. 2. Ensure safety and tolerability of single, subcutaneous administration of Eutropin formulations to healthy male volunteers.

Timeline

Start
2017-05-31
Primary completion
2017-07-10
Completion
2017-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Eutropin Protein / enzyme biologic 4 iu Subcutaneous
Subject Eutropin Protein / enzyme biologic 12 iu Subcutaneous
Subject Eutropin Protein / enzyme biologic 36 iu Subcutaneous

Indications

No indication recorded.